Antitumor Effects of the Proteasome Inhibitor Bortezomib in Medullary and Anaplastic Thyroid Carcinoma Cells in Vitro

• Published in: The journal of clinical endocrinology and metabolism 2006-10, Vol.91 (10), p.4013-4021
• Main Authors: Mitsiades, Constantine S., McMillin, Douglas, Kotoula, Vassiliki, Poulaki, Vassiliki, McMullan, Ciaran, Negri, Joseph, Fanourakis, Galinos, Tseleni-Balafouta, Sophia, Ain, Kenneth B., Mitsiades, Nicholas
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - pharmacology; Apoptosis - drug effects; BH3 Interacting Domain Death Agonist Protein - metabolism; Biological and medical sciences; Boronic Acids - pharmacology; Bortezomib; Carcinoma - drug therapy; Carcinoma, Medullary - drug therapy; Caspases - physiology; Cell Cycle - drug effects; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21 - analysis; Doxorubicin - pharmacology; Endocrinopathies; Enzyme Inhibitors - pharmacology; Fundamental and applied biological sciences. Psychology; Humans; Insulin-Like Growth Factor I - pharmacology; Malignant tumors; Medical sciences; NF-kappa B - antagonists & inhibitors; NF-kappa B - metabolism; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins c-jun - metabolism; Pyrazines - pharmacology; Thyroid Neoplasms - drug therapy; Thyroid Neoplasms - pathology; Thyroid. Thyroid axis (diseases); Tumor Suppressor Protein p53 - analysis; Vertebrates: endocrinology
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2005-2472

Context: The ubiquitin-proteasome pathway is a major pathway for degradation of intracellular proteins. Proteasome inhibitors constitute a novel class of antitumor agents with preclinical and clinical evidence of activity against hematological malignancies and solid tumors. The proteasome inhibitor bortezomib (PS-341, Velcade) has been approved by the Food and Drug Administration for the treatment of multiple myeloma and is being studied intensely in several other malignancies. Its mechanism of action is complex but appears to include the inhibition of inhibitory-κB degradation, which leads to inactivation of the transcriptional factor nuclear factor-κB (NF-κB). NF-κB has been implicated in the pathophysiology of the most aggressive forms of thyroid carcinoma, i.e. medullary and anaplastic. Objective and Methods: We evaluated the effect of bortezomib on a panel of thyroid carcinoma cell lines, originating from papillary, follicular, anaplastic, and medullary carcinomas. Results: Bortezomib induced apoptosis in medullary and anaplastic cell lines with IC50 values well within the range of clinically achievable concentrations and much lower than respective IC50 values for other solid malignancies. Bortezomib inhibited NF-κB activity; increased p53, p21, and jun expression; and induced caspase-dependent apoptosis. Sensitivity of thyroid carcinoma cells to bortezomib was partially decreased by overexpression of Bcl-2 or treatment with IGF-I, whereas the combination of bortezomib with chemotherapy (doxorubicin) was synergistic. Conclusions: These data provide both insights into the molecular mechanisms of antitumor activity of proteasome inhibitors and the rationale for future clinical trials of bortezomib, alone or in combination with conventional chemotherapy, to improve patient outcome in medullary and anaplastic thyroid carcinomas.